STERIS plc (NYSE:STE) Given Consensus Rating of “Moderate Buy” by Analysts

STERIS plc (NYSE:STE) has earned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $273.50.

A number of research analysts have issued reports on the company. Morgan Stanley lifted their price objective on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. KeyCorp increased their price target on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a report on Tuesday, July 22nd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th.

STERIS Trading Up 0.1%

NYSE STE opened at $257.15 on Friday. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $25.24 billion, a PE ratio of 39.38 and a beta of 1.02. The stock’s 50 day moving average is $246.32 and its 200 day moving average is $240.93. STERIS has a twelve month low of $200.98 and a twelve month high of $268.30.

STERIS (NYSE:STE) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same period in the prior year, the firm earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Research analysts forecast that STERIS will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s dividend payout ratio is presently 36.21%.

Insider Buying and Selling at STERIS

In related news, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the sale, the chief executive officer directly owned 51,096 shares in the company, valued at approximately $12,356,034.72. This trade represents a 0.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the transaction, the vice president directly owned 33,669 shares of the company’s stock, valued at approximately $8,926,998.66. This trade represents a 30.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.07% of the company’s stock.

Institutional Investors Weigh In On STERIS

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in STERIS by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider’s stock valued at $3,022,114,000 after buying an additional 50,393 shares during the last quarter. State Street Corp increased its position in STERIS by 4.0% during the third quarter. State Street Corp now owns 4,354,839 shares of the medical equipment provider’s stock valued at $1,077,564,000 after acquiring an additional 166,736 shares during the last quarter. Generation Investment Management LLP lifted its holdings in STERIS by 5.4% in the first quarter. Generation Investment Management LLP now owns 3,354,545 shares of the medical equipment provider’s stock valued at $760,308,000 after acquiring an additional 170,392 shares during the period. Geode Capital Management LLC boosted its position in STERIS by 1.9% in the second quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider’s stock worth $592,980,000 after purchasing an additional 46,859 shares during the last quarter. Finally, Orbis Allan Gray Ltd grew its stake in shares of STERIS by 36.0% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after purchasing an additional 556,088 shares during the period. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.